Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) major shareholder Sessa Capital (Master), L.P. sold 3,000,000 shares of the company’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $9.40, for a total transaction of $28,200,000.00. Following the completion of the sale, the insider now owns 11,879,023 shares in the company, valued at approximately $111,662,816.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Provention Bio Price Performance
Shares of NASDAQ:PRVB opened at $9.04 on Friday. The firm’s 50 day moving average is $9.30 and its two-hundred day moving average is $6.70. The company has a current ratio of 7.58, a quick ratio of 7.58 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $788.21 million, a P/E ratio of -5.79 and a beta of 2.29. Provention Bio, Inc. has a 52 week low of $3.18 and a 52 week high of $10.88.
Provention Bio (NASDAQ:PRVB – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.12. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.88 million. Provention Bio had a negative net margin of 3,791.21% and a negative return on equity of 99.08%. Analysts anticipate that Provention Bio, Inc. will post -1.66 earnings per share for the current year.
Analyst Upgrades and Downgrades
Institutional Trading of Provention Bio
A number of large investors have recently added to or reduced their stakes in PRVB. Vanguard Group Inc. boosted its holdings in Provention Bio by 39.9% during the third quarter. Vanguard Group Inc. now owns 3,604,065 shares of the company’s stock worth $16,219,000 after buying an additional 1,027,113 shares in the last quarter. Bioimpact Capital LLC bought a new stake in Provention Bio during the second quarter worth approximately $2,370,000. BlackRock Inc. boosted its holdings in Provention Bio by 9.2% during the third quarter. BlackRock Inc. now owns 5,030,348 shares of the company’s stock worth $22,637,000 after buying an additional 424,311 shares in the last quarter. Palo Alto Investors LP bought a new stake in Provention Bio during the third quarter worth approximately $1,759,000. Finally, Invesco Ltd. boosted its holdings in Provention Bio by 967.2% during the first quarter. Invesco Ltd. now owns 226,708 shares of the company’s stock worth $1,659,000 after buying an additional 205,464 shares in the last quarter. 37.39% of the stock is currently owned by institutional investors.
Provention Bio Company Profile
Provention Bio, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset.
- Get a free copy of the StockNews.com research report on Provention Bio (PRVB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.